The Procyrion device consists of a small, continuous flow pump mounted within a self-expanding anchoring system. The device is advanced through a catheter in the femoral artery to the descending thoracic aorta. The self-expanding anchors deploy to fix the pump to the aortic wall. Following deployment, the catheter is fully removed, leaving only the anchored pump and a small diameter, flexible electrical power wire which may be tunneled to a desired transdermal exit site or to a Transcutaneous Energy Transfer (TET) system for subcutaneous implantation without an indwelling power lead. Compared to traditional LVADs, Procyrion replaces a major surgery and a lengthy hospital stay with a minimally invasive outpatient procedure. An opportunity to rest and heal the heart The focus of circulatory support for nearly 50 years has been to replace the function of the ailing heart. This has resulted in large, cumbersome surgical devices that provide full circulatory support. Recent clinical evidence from partial circulatory support devices (B.P. Meyns et al. / European Journal of Cardio-thoracic Surgery 39 2011 693—698) and cardiac resynchronization therapy devices (Sutton et al. Circulation. 2003;107:1985-1990) suggests that the class III heart failure patient can benefit from partial circulatory support. The Procyrion device seeks to reduce afterload, reduce workload of the heart, and increase end-organ perfusion. Together, these factors provide the potential to rest and heal the heart thereby improving patient quality of life and reducing the cost of heart failure.